Next-Gen Tau Tracer

About Life Molecular Imaging

Life Molecular Imaging is a commercial-stage diagnostics company acquired by Lantheus in 2025, originating from Bayer's R&D portfolio. Its core business is developing and supplying innovative PET tracers, with its flagship product, Neuraceq® (florbetaben F18), approved for beta-amyloid imaging in Alzheimer's disease evaluation. The company operates a global supply network for clinical trials and commercial use, with a pipeline targeting next-generation tracers for Tau, MAO-B, and cardiac amyloidosis. Its model integrates proprietary tracer development with pharma collaboration services.

Therapeutic Areas